Skip to main content
Clinical Trials/CTRI/2021/03/032150
CTRI/2021/03/032150
Not yet recruiting
Phase 2

Clinical study to Evaluate Safety And Efficacy of Bozidan(Pyrethrum Indicum)in the management of Niqris Muzmin (Chronic Gout).

Central council for Research in Unani Medicine New Delhi0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: M1A9- Chronic gout, unspecified
Sponsor
Central council for Research in Unani Medicine New Delhi
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Central council for Research in Unani Medicine New Delhi

Eligibility Criteria

Inclusion Criteria

  • Irrespective of all genders
  • Patients between 18\-65 years of age
  • Patients Fulfilling the criteria of American College of Rheumatology(ACR) for diagnosing gouty arthritis including clinical features, laboratory and radiological finding , having serum uric acid level \>7mg/dl in males and Ë?6mg/dl in females17\.
  • Patients, who are ready to sign the informed consent, follow the protocol and willing to participate in clinical study voluntarily

Exclusion Criteria

  • Patients below 18 and above 65 years of age
  • Pregnant and lactating mothers
  • Patients who fail to give consent
  • Patients of gout associated with any systemic disorder which interfere with patient study
  • Patients of gout associated with any severe arthritic condition such as rheumatoid arthritis, septic arthritis.
  • Patients suffering from anemia and other blood dyscrasias like leukemia, haemophilia,etc
  • Patients suffering from congenital gout
  • Any other disease other than Gout(Gouty arthritis).

Outcomes

Primary Outcomes

Not specified

Similar Trials